Adlai Nortye Ltd. ALN 深 沪
交易中 08-25 11:45:15 美东时间
0.00
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 总市值 0
- 52周最高 0.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 273.43万
- 历史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 0.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adlai Nortye Submits Clinical Trial Notification To Australia's TGA And Receives Approval From HREC To Commence Phase I Clinical Trial Evaluating AN4035 For Treatment Of CEACAM5-Enriched RAS-Addicted Solid Tumors
First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and China NMPA are in process SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Adl...
08-03 19:04
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
Adlai Nortye Ltd. has submitted a Clinical Trial Notification (CTN) to Australia's TGA and received HREC approval to commence a phase I clinical trial for AN4035, a first-in-class CEACAM5-targeting, pan-RAS(ON) inhibitor-based ADC for treating CEACAM5-enriched RAS-addicted solid tumors. AN4035 is the first pan-RAS(ON) ADC to enter global clinical development, utilizing targeted delivery to localize tumor activity and minimize systemic toxicity. T...
08-03 11:00
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
Adlai Nortye Ltd. expanded its Scientific Advisory Board (SAB) by appointing Dr. David S. Hong and Dr. Piro Lito, leading medical oncologists, to provide expertise in RAS biology and targeted therapies. The company's pipeline includes RAS inhibitors like AN9025 and AN4035, as well as immunotherapies like AN8025. The new SAB members will support the company's global development of innovative cancer therapies.
07-13 11:00
TeraWulf, BRP And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
US stock futures down, TeraWulf Inc. (WULF) shares fall after preliminary results & stock offering. Other stocks moving lower in pre-market trading.
04-15 20:02
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
Adlai Nortye Ltd. announced the initiation of its Phase 1 clinical trial for AN9025, a pan-RAS(ON) inhibitor, with the first U.S. patient dosed in early February. The trial, a first-in-human, multicenter, open-label study, aims to assess safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with advanced or metastatic solid tumors harboring RAS mutations. Conducted in collaboration with Jiangsu Aosaikang Pharmaceutical Co. L...
02-12 09:00
Adlai Nortye Announces $140M Private Placement Equity Financing
Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into securities
02-03 20:45
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
Adlai Nortye Ltd., a clinical-stage biotechnology company focused on innovative cancer therapies, has raised approximately $140 million through a private placement of 64,615,386 Class A ordinary shares, equivalent to 21,538,462 ADSs, priced at $2.1667 per share ($6.50 per ADS). The placement was co-led by Cormorant Asset Management and Columbia Threadneedle Investments, with participation from new and existing investors including Balyasny Asset M...
02-03 12:00
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
Adlai Nortye与ASK Pharm签署AN9025独家许可协议，授权其在 mainland China, Hong Kong, and Macau 开发、生产和商业化。Adlai Nortye将保留全球权利，预计获得高达16亿元人民币的总付款，包括首付款、里程碑付款及销售分成。AN9025是潜在同类最佳的pan-RAS(ON)抑制剂，针对多种肿瘤类型的RAS突变，预计2026年Q1启动I期临床试验。此次合作旨在加速RAS突变癌症患者的治疗开发。
2025-12-29 11:00
Adlai Nortye Ltd. Shareholders Approve Redomiciliation to Singapore
Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) has provided an announcement. Adlai ...
2025-12-03 19:27
